Compare AORT & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AORT | WGS |
|---|---|---|
| Founded | 1984 | 2017 |
| Country | United States | United States |
| Employees | N/A | 1300 |
| Industry | Medical/Dental Instruments | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 1996 | N/A |
| Metric | AORT | WGS |
|---|---|---|
| Price | $22.45 | $52.04 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | $49.40 | ★ $120.71 |
| AVG Volume (30 Days) | 831.0K | ★ 2.0M |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 165.62 | N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $298,836,000.00 | N/A |
| Revenue This Year | $14.20 | $29.98 |
| Revenue Next Year | $11.20 | $25.92 |
| P/E Ratio | ★ $748.50 | $1,251.58 |
| Revenue Growth | ★ 18.01 | N/A |
| 52 Week Low | $19.16 | $32.21 |
| 52 Week High | $48.25 | $170.87 |
| Indicator | AORT | WGS |
|---|---|---|
| Relative Strength Index (RSI) | 26.54 | 51.70 |
| Support Level | $21.76 | $32.21 |
| Resistance Level | $24.70 | $73.46 |
| Average True Range (ATR) | 1.19 | 3.45 |
| MACD | 0.06 | 1.96 |
| Stochastic Oscillator | 12.08 | 96.51 |
Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others. The company's has two reportable segments: Medical Devices and Preservation Services. The Medical Devices segment includes revenues from sales of aortic stent grafts, surgical sealants, On-X products, and other product revenues. The Preservation Services segment includes services revenues from the preservation of cardiac and vascular implantable human tissues. Company operates in North America, EMEA. LATAM, APAC. Maximum revenue is from North America.
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.